Condition: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic Syndromes · Sponsor: Ellipses Pharma
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
This description comes directly from the study's public registry record.
Clinical Trials Team · +44 20 3743 0992 · Enquiries@ellipses.life
Always discuss trial participation with your own doctor first.
| Royal Perth Hospital | Perth, Western Australia, Australia | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
| Erasmus MC | Rotterdam, Netherlands | Recruiting |
| The Royal Marsden | London, UK, United Kingdom | Recruiting |
| University College London Hospital | London, United Kingdom | Recruiting |
| The Christie Hospital | Manchester, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04581512